Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Kaseb, Ahmed O ^a   Xiao, Lianchun ^b   Hassan, Manal M ^a   Chae, Young Kwang ^a   Lee, Ju Seog ^b   Vauthey, Jean Nicolas ^b   Krishnan, Sunil ^b   Cheung, Sheree ^a   Hassabo, Hesham M ^a   Aloia, Thomas ^b   Conrad, Claudius ^b   Curley, Steven A ^b   Vierling, John M ^a   Jalal, Prasun ^a   Raghav, Kanwal ^a   Wallace, Michael ^b   Rashid, Asif ^b   Abbruzzese, James L ^a   Wolff, Robert A ^a   Morris, Jeffrey S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; AGED; ARTICLE; ASCITES; BLOOD SAMPLING; BRAIN DISEASE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD TURCOTTE PUGH SCORE; COHORT ANALYSIS; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; INSULIN LIKE GROWTH FACTOR 1 BLOOD LEVEL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; TUMOR VOLUME; VALIDATION STUDY; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; KAPLAN MEIER METHOD; LIVER; LIVER TUMOR; METABOLISM; METHODOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY;

CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84905161621     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju088     Document Type: Article

References (35)

1. Child CG. Remote results of portal surgery in liver cirrhosis. Rev Int Hepatol. 1964;14:287-288.
2. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.
3. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711.
4. Wilson SR, Greig P, Kaseb AO. Pretreatment assessment of hepa-tocellular cancer: expert consensus conference. HPB (Oxford). 2010;12(5):300-301.
5. Vauthey JN, Dixon E, Abdalla EK, et al. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12(5):289-299.
6. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(Suppl1):S100-S107.
7. Oellerich M, Burdelski M, Lautz HU, et al. Assessment of pre-transplant prognosis in patients with cirrhosis. Transplantation. 1991;51(4):801-806.
8. Testa R, Valente U, Risso D, et al. Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? Eur J Gastroenterol Hepatol. 1999;11(5):559-563.
9. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (Baltimore). 2000;31(4):864-871.
10. Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52(1):134-139.
11. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127-137.
12. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev. 1995;16(1):3-34.
13. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (New York). 1998;279(5350):563-566.
14. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393-1396.
15. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91(7):620-625.
16. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst. 1999;91(2):151-156.
17. Buzzelli G, Dattolo P, Pinzani M, et al. Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol. 1993;88(10):1744-1748.
18. Luo SM, Tan WM, Deng WX, et al. Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol. 2005;11(27):4272-4276.
19. Stuver SO, Kuper H, Tzonou A, et al. Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer. 2000;87(1):118-121.
20. Su WW, Lee KT, Yeh YT, et al. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal. 2010;24(3):195-200.
21. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2007;17(4):493-503.
22. Volzke H, Nauck M, Rettig R, et al. Association between hepatic steato-sis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol. 2009;161(5):705-713.
23. Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol. 2010;16(13):1639-1643.
24. Bonefeld K, Moller S. Insulin-like growth factor-I and the liver. Liver Int. 2011;31(7):911-919.
25. Mitchell R, McDermid J, Ma MM, et al. MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease. World J Hepatol. 2011;3(6):157-163.
26. Rehem RN, El-Shikh WM. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology. 2011;58(107-108):949-954.
27. Wu YL, Ye J, Zhang S, Zhong J, et al. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol. 2004;10(18):2740-2743.
28. Colak Y, Senates E, Ozturk O, et al. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol. 2012;24(3):255-261.
29. Castro GR, Coelho JC, Parolin MB, et al. Insulin-like growth factor I correlates with MELD and returns to normal level after liver transplantation. Ann Transpl. 2013;18:57-62.
30. Assy N, Pruzansky Y, Gaitini D, et al. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol. 2008;49(1):34-42.
31. Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011;29(29):3892-3899.
32. Kaseb AO, Abbruzzese JL, Vauthey JN, et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80(5-6):373-381.
33. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore). 2005;42(5):1208-1236.
34. Grambsch PMaT, TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526
35. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91-96.